Clinical trials · Boston, MA
Advanced Solid Tumor clinical trials in Boston
We’re tracking 187 recruiting advanced solid tumor studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Boston, MassachusettsAges 8 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Boston, MassachusettsAges 1 month–17 years - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Boston, MassachusettsAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Boston, MassachusettsAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Boston, MassachusettsAges 18 years+ - NCT05007782RecruitingPhase 1
Testing a new immune drug for advanced solid tumors
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
Boston, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Boston, MassachusettsAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Boston, MassachusettsAges 12 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Boston, MassachusettsAges 18 years+ - NCT06983743RecruitingPhase 1
ERAS-0015 for Advanced Solid Tumors With RAS Mutations
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
Boston, MassachusettsAges 18–99 - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Boston, MassachusettsAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Boston, MassachusettsAges 18–130 - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Boston, MassachusettsAges 18 years+ - NCT05836324RecruitingPhase 1
Safety study of an anti-cancer drug for advanced tumors
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
Boston, MassachusettsAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Boston, MassachusettsAges 12 years+ - NCT07584226RecruitingPhase 1
Testing RLY-8161 for advanced cancers with NRAS mutations
This trial tests a new drug called RLY-8161 in people with advanced solid tumors (cancer that has spread) that have a specific genetic mutation called NRAS. The drug is designed to target this mutation and may help slow or shrink tumors that haven't responded to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+
Hear when a new Advanced Solid Tumor trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Advanced Solid Tumor trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting advanced solid tumor studies listed above.
- Dana-Farber Cancer Institute · 13 studies
- Massachusetts General Hospital · 8 studies
- Research Site · 3 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Avenzo Therapeutics Recruiting Site
- Exelixis Clinical Site
- GSK Investigational Site
- Lifespan Cancer Institute
What taking part in a advanced solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced solid tumor studies in Massachusetts.
Common questions
- Are there advanced solid tumor clinical trials near Boston?
- Yes. We're currently tracking 187 recruiting advanced solid tumor studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced solid tumor study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced solid tumor studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.